EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tacrine-Based Hybrids: Past, Present, and Future

Anna Bubley, Alexaner Erofeev, Peter Gorelkin iD, Elena Beloglazkina iD, Alexander Majouga, Olga Krasnovskaya

International Journal of Molecular Sciences · 15.01.2023 · 24 (2) · 1717

DOI: 10.3390/ijms24021717 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.01.2023. Verfasst von Anna Bubley und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Department, Lomonosov Moscow State University, Leninskie Gory 1-3, Moscow 119991, Russia. Hauptthemen laut MEDLINE: Alzheimer Disease, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Education and Science of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a neurodegenerative disorder which is characterized by β-amyloid (Aβ) aggregation, τ-hyperphosphorylation, and loss of cholinergic neurons. The other important hallmarks of AD are oxidative stress, metal dyshomeostasis, inflammation, and cell cycle dysregulation. Multiple therapeutic targets may be proposed for the development of anti-AD drugs, and the “one drug–multiple targets” strategy is of current interest. Tacrine (THA) was the first clinically approved cholinesterase (ChE) inhibitor, which was withdrawn due to high hepatotoxicity. However, its high potency in ChE inhibition, low molecular weight, and simple structure make THA a promising scaffold for developing multi-target agents. In this review, we summarized THA-based hybrids published from 2006 to 2022, thus providing an overview of strategies that have been used in drug design and approaches that have resulted in significant cognitive improvements and reduced hepatotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseChemical and Drug Induced Liver InjuryHumansTacrineCholinesterase InhibitorsAmyloid beta-PeptidesAcetylcholinesterase

Stichwörter der Autor:innen

Alzheimeracetylcholinesteraseamyloid-βbutyrylcholinesterasetacrine

Substanzen

TacrineCholinesterase InhibitorsAmyloid beta-PeptidesAcetylcholinesterase

Autor:innen und Institutionen

  • Chemistry Department, Lomonosov Moscow State University, Leninskie Gory 1-3, Moscow 119991, Russia.
  • Department of Materials Science of Semiconductors and Dielectrics, National University of Science and Technology (MISIS), Leninskiy Prospect 4, Moscow 119049, Russia.

ORCID-Profile: Peter Gorelkin, Elena Beloglazkina

Förderung

  • The Ministry of Education and Science of the Russian Federation

Zitieren

APA

Bubley, A., Erofeev, A., Gorelkin, P., Beloglazkina, E., Majouga, A., & Krasnovskaya, O. (2023). Tacrine-Based Hybrids: Past, Present, and Future. International Journal of Molecular Sciences, 24(2), 1717. https://doi.org/10.3390/ijms24021717

Vancouver

Bubley A, Erofeev A, Gorelkin P, Beloglazkina E, Majouga A, Krasnovskaya O. Tacrine-Based Hybrids: Past, Present, and Future. International Journal of Molecular Sciences. 2023;24(2):1717. doi:10.3390/ijms24021717

BibTeX
@article{Bubley2023,
  author = {Bubley, Anna and Erofeev, Alexaner and Gorelkin, Peter and Beloglazkina, Elena and Majouga, Alexander and Krasnovskaya, Olga},
  title = {Tacrine-Based Hybrids: Past, Present, and Future},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {2},
  pages = {1717},
  doi = {10.3390/ijms24021717}
}
Kostenlos starten →